Log in
Enquire now
Kaleido Biosciences

Kaleido Biosciences

Kaleido Biosciences is a biotechnology company making discoveries in genetic and metabolic diversity of the human microbiome into treatment and therapies for a wide range of diseases.

OverviewStructured DataIssuesContributorsActivity

Contents

kaleido.com
Is a
Organization
Organization
Company
Company

Company attributes

Industry
Biomedical engineering
Biomedical engineering
Technology
Technology
Biology
Biology
Biopharmaceutical
Biopharmaceutical
Microbiome
Microbiome
Engineering
Engineering
Microbiology
Microbiology
...
Location
United States
United States
Lexington, Massachusetts
Lexington, Massachusetts
Bedford, Massachusetts
Bedford, Massachusetts
Massachusetts
Massachusetts
B2X
B2B
B2B
CEO
‌
Daniel Menichella
Founder
Geoffrey von Maltzahn
Geoffrey von Maltzahn
Noubar Afeyan
Noubar Afeyan
Pitchbook URL
pitchbook.com/profiles...149977-00
Legal Name
Kalleido Biosciences, Inc.
Legal classification
Incorporation (business)
Incorporation (business)
Corporation
Corporation
Number of Employees (Ranges)
51 – 2000
Number of Employees
680
Full Address
65 Hayden Ave Lexington​, MA, 02421-7994 United States
CIK Number
1,751,2990
Place of Incorporation
Delaware
Delaware
0
Investors
Rock Springs Capital
Rock Springs Capital
Flagship Pioneering
Flagship Pioneering
Abu Dhabi Investment Authority
Abu Dhabi Investment Authority
Fidelity Investments
Fidelity Investments
Olive Tree Capital
Olive Tree Capital
0
Invus
Invus
DUNS Number
0800907570
Founded Date
2015
0
Total Funding Amount (USD)
230,900,000
Latest Funding Round Date
February 4, 2021
Competitors
Homology Medicines
Homology Medicines
Pivot Bio
Pivot Bio
Gelesis
Gelesis
Exchange
Nasdaq
Nasdaq
Glassdoor ID
1457549
CFO
‌
William Duke
Latest Funding Type
Series C
Series C
CAGE Code
8EH060
Patents Assigned (Count)
5
Country
United States
United States

Other attributes

Company Operating Status
Active
SIC Code
2,8360
Ticker Symbol
KLDO
Overview

Kaleido Biosciences is a biotechnology company making discoveries in genetic and metabolic diversity of the human microbiome into treatment and therapies for a wide range of diseases that is headquartered in Bedford, Massachusetts and was founded in 2015 by Geoffrey von Maltzahn and Noubar Afeyan.

Funding
Venture

On September 17, 2017 Kaleido Biosciences completed a venture capital round that brought thier total amount of funding to date to $65 million. The round was led by Flagship Pioneering (lead investor and a number of institutional and individual investors which included Mike Bonney. At the time of announcing their venture funding the company also announced that Mike Bonney will be joining the Kaleido management team and board of directors.

Series C

On June 25, 2018 Kaleido Biosciences announced completing their oversubscribed series C funding round with $101 million in funding from Abu Dhabi Investment Authority (ADIA), Fidelity Management and Research Company, Invus, and Rock Springs Capital, Flagship Pioneering, and several undisclosed investors. The company plans on using their series C funding to accelerate the development of its product pipeline by conducting multiple clinical trials in several therapeutic areas of interest to the company.

Timeline

No Timeline data yet.

Funding Rounds

Products

Acquisitions

SBIR/STTR Awards

Patents

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more companies like Kaleido Biosciences

Use the Golden Query Tool to find similar companies in the same industry, location, or by any other field in the Knowledge Graph.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.